EUVIMEDEUVIMED entdecken
Open Access

Moving away from one disease at a time: Screening, trial design, and regulatory implications of novel platform technologies

Julie Lekstrom-Himes iD, P J Brooks iD, Dwight D Koeberl iD, Amy Brower iD, Aaron Goldenberg iD, Robert C Green iD, Jill A Morris iD, Joseph J Orsini, Timothy W Yu iD, Erika F Augustine iD

American Journal of Medical Genetics Part C: Seminars in Medical Genetics · 2023-03 · 193 (1) · 30-43

DOI: 10.1002/ajmg.c.32031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Medical Genetics Part C: Seminars in Medical Genetics, online erschienen am 04.02.2023. Verfasst von Julie Lekstrom-Himes und 9 weiteren Autor:innen. Beteiligte Einrichtung: Takeda, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Rare Diseases, Gene Editing. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NINDS NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Most rare diseases are caused by single‐gene mutations, and as such, lend themselves to a host of new gene‐targeted therapies and technologies including antisense oligonucleotides, phosphomorpholinos, small interfering RNAs, and a variety of gene delivery and gene editing systems. Early successes are encouraging, however, given the substantial number of distinct rare diseases, the ability to scale these successes will be unsustainable without new development efficiencies. Herein, we discuss the need for genomic newborn screening to match pace with the growing development of targeted therapeutics and ability to rapidly develop individualized therapies for rare variants. We offer approaches to move beyond conventional “one disease at a time” preclinical and clinical drug development and discuss planned regulatory innovations that are necessary to speed therapy delivery to individuals in need. These proposals leverage the shared properties of platform classes of therapeutics and innovative trial designs including master and platform protocols to better serve patients and accelerate drug development. Ultimately, there are risks to these novel approaches; however, we believe that close partnership and transparency between health authorities, patients, researchers, and drug developers present the path forward to overcome these challenges and deliver on the promise of gene‐targeted therapies for rare diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rare DiseasesGene EditingInfant, NewbornHumansGenetic TherapyGenomics

Autor:innen und Institutionen

  • Takeda, Cambridge, Massachusetts, USA.
  • Division of Rare Diseases Research Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, Maryland, USA.
  • Division of Medical Genetics, Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina, USA.
  • American College of Medical Genetics and Genomics, Bethesda, Maryland, USA.
  • Department of Bioethics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
  • Mass General Brigham, Broad Institute, Ariadne Labs and Harvard Medical School, Boston, MA, USA.

ORCID-Profile: Julie Lekstrom-Himes, P J Brooks, Dwight D Koeberl, Amy Brower, Aaron Goldenberg, Robert C Green, Jill A Morris, Timothy W Yu, Erika F Augustine

Förderung

  • NICHD NIH HHS
  • NINDS NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Lekstrom-Himes, J., Brooks, P. J., Koeberl, D. D., Brower, A., Goldenberg, A., Green, R. C., Morris, J. A., Orsini, J. J., Yu, T. W., & Augustine, E. F. (2023). Moving away from one disease at a time: Screening, trial design, and regulatory implications of novel platform technologies. American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 193(1), 30-43. https://doi.org/10.1002/ajmg.c.32031

Vancouver

Lekstrom-Himes J, Brooks PJ, Koeberl DD, Brower A, Goldenberg A, Green RC, et al. Moving away from one disease at a time: Screening, trial design, and regulatory implications of novel platform technologies. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2023;193(1):30-43. doi:10.1002/ajmg.c.32031

BibTeX
@article{LekstromHimes2023,
  author = {Lekstrom-Himes, Julie and Brooks, P J and Koeberl, Dwight D and Brower, Amy and Goldenberg, Aaron and Green, Robert C and Morris, Jill A and Orsini, Joseph J and Yu, Timothy W and Augustine, Erika F},
  title = {Moving away from one disease at a time: Screening, trial design, and regulatory implications of novel platform technologies},
  journal = {American Journal of Medical Genetics Part C: Seminars in Medical Genetics},
  year = {2023},
  volume = {193},
  number = {1},
  pages = {30--43},
  doi = {10.1002/ajmg.c.32031}
}
Kostenlos starten →